C
인트론바이오
048530KOSDAQ기초 의약물질 제조업53.0 / 100
Reference Date: 2026-04-13
Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 23.9% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
IntronBio focuses on developing biopharmaceuticals based on bacteriophage technology and molecular diagnostic solutions. The company's drug development division targets antibiotic-resistant bacterial infections and immune therapies, while its diagnostic division produces molecular test kits, including COVID-19 diagnostic products, contributing to revenue.
Number of Employees
77people
Average Salary
64.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 33.454.0Point
PBR
1.67Industry Average 2.034.0Point
In line with industry avg
ROE
-11.66Industry Average -4.293.5Point
2.7x industry avg (excellent)
Debt Ratio
0.52Industry Average 6.618.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼21.8% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼55.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -8.0% (declining, 3yr)
Detailed News Sentiment
2 totalPositive 0Neutral 0Negative 0
- Neutral
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (20%)
Current 3,685Won52-week high 6,65052-week low 2,915
1-month return0.0Point
1m -23.86% (strong drop)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
7 totalPositive 1Neutral 6Negative 0
- Neutral주식소각결정2026-04-02
- Neutral신탁계약해지결과보고서2026-04-02
- Positive주요사항보고서(자기주식취득신탁계약해지결정)2026-04-02
- Neutral신탁계약에의한취득상황보고서2026-04-02
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26